1. Pyrimidine Triones as Potential Activators of p53 Mutants.
- Author
-
Fallatah, Maryam, Demir, Özlem, Law, Fiona, Lauinger, Linda, Baronio, Roberta, Hall, Linda, Bournique, Elodie, Srivastava, Ambuj, Metzen, Landon, Norman, Zane, Buisson, Remi, Amaro, Rommie, and Kaiser, Peter
- Subjects
CETSA ,DSF ,cancer ,mutant p53 ,p53 corrector ,p53 reactivator ,tumor suppressor ,Humans ,Tumor Suppressor Protein p53 ,Pyrimidines ,Cell Proliferation ,Cell Line ,Tumor ,Mutation ,Antineoplastic Agents ,Neoplasms - Abstract
p53 is a crucial tumor suppressor in vertebrates that is frequently mutated in human cancers. Most mutations are missense mutations that render p53 inactive in suppressing tumor initiation and progression. Developing small-molecule drugs to convert mutant p53 into an active, wild-type-like conformation is a significant focus for personalized cancer therapy. Prior research indicates that reactivating p53 suppresses cancer cell proliferation and tumor growth in animal models. Early clinical evidence with a compound selectively targeting p53 mutants with substitutions of tyrosine 220 suggests potential therapeutic benefits of reactivating p53 in patients. This study identifies and examines the UCI-1001 compound series as a potential corrector for several p53 mutations. The findings indicate that UCI-1001 treatment in p53 mutant cancer cell lines inhibits growth and reinstates wild-type p53 activities, including DNA binding, target gene activation, and induction of cell death. Cellular thermal shift assays, conformation-specific immunofluorescence staining, and differential scanning fluorometry suggest that UCI-1001 interacts with and alters the conformation of mutant p53 in cancer cells. These initial results identify pyrimidine trione derivatives of the UCI-1001 series as candidates for p53 corrector drug development.
- Published
- 2024